In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally disorder progression or perhaps the contributors are unable to tolerate the study drugs. - "Our study disclosed the critical function with the KLF16/MYC regulatory axis https://abbv-744-in-the-treatment57957.bloggactivo.com/31335018/getting-my-abbv-744-brd4-inhibitor-clinical-efficacy-in-refractory-cancers-to-work